Oct. 10 at 2:32 PM
$IMTX Has multiple readouts in Q4'25, including data at ESMO on October 20. The company's cell therapy has advantages over
$IOVA's lifileucel, although only applies to 40-50% of advanced melanoma patients.
https://seekingalpha.com/article/4829111-immatics-multiple-clinical-catalysts-in-q425-and-2026